Seer, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Seer, Inc. on July 7, 2025, regarding events occurring at the Company's 2025 Annual Meeting of Stockholders held on the same date. The Company is incorporated in Delaware and its Class A Common Stock trades on The NASDAQ Global Select Market under the symbol "SEER."
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Corporate Actions
- Nasdaq Listing Non-Compliance: The Company notified Nasdaq that it will no longer be in compliance with Listing Rule 5605(c)(2)(A) following the Annual Meeting. The non-compliance relates to the Audit Committee composition, which currently fails to meet the requirement of having at least three members, with at least one member possessing specific financial sophistication or experience.
- Cure Period: The Company intends to rely on the cure period provided under Nasdaq Listing Rule 5605(c)(4)(B) to regain compliance by evaluating and adjusting the membership of its Board and Board committees.
- Annual Meeting Results: Approximately 90.16% of eligible votes were represented at the meeting. Stockholders elected six directors and ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding the Company's intent to regain compliance with Nasdaq listing standards. It notes that actual results may differ due to risks and uncertainties described in other SEC filings (10-K, 10-Q). No specific financial guidance or operational outlook was provided in this document.
Investor Verification Checklist
- Verify the timeline and specific actions Seer, Inc. plans to take to cure the Audit Committee composition deficiency before the Nasdaq cure period expires.
- Review the composition of the newly elected Board of Directors to assess future governance stability.
- Monitor subsequent filings for any updates on the Company's compliance status with Nasdaq Listing Rules.
- Check the most recent 10-Q or 10-K for the latest financial position, as this 8-K contains no financial data.